Julie Burek Biography and Net Worth

Julie Burek is Vice President-Finance for Voyager Therapeutics, Inc.

In the past she was Senior Manager-Finance at Biogen, Inc.

Ms. Burek received an undergraduate degree from Bentley University and an MBA from Northeastern University.

How do I contact Julie Burek?: The corporate mailing address for Ms. Burek and other Voyager Therapeutics executives is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. Voyager Therapeutics can also be reached via phone at (857) 259-5340 and via email at [email protected]. Learn More on Julie Burek's contact information.
Has Julie Burek been buying or selling shares of Voyager Therapeutics?: Julie Burek has not been actively trading shares of Voyager Therapeutics during the last ninety days. Most recently, Julie Burek sold 265 shares of the business's stock in a transaction on Wednesday, January 12th. The shares were sold at an average price of $3.06, for a transaction totalling $810.90. Learn More on Julie Burek's trading history.
Are insiders buying or selling shares of Voyager Therapeutics?: In the last year, insiders at the sold shares 3 times. They sold a total of 9,808 shares worth more than $62,186.51. The most recent insider tranaction occured on October, 2nd when insider Sandell Jacquelyn Fahey sold 5,999 shares worth more than $34,914.18. Insiders at Voyager Therapeutics own 4.5% of the company. Learn More about insider trades at Voyager Therapeutics.
Information on this page was last updated on 10/2/2024.

Julie Burek Insider Trading History at Voyager Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/12/2022	Sell	265	$3.06	$810.90
1/3/2022	Sell	3,063	$2.83	$8,668.29

Julie Burek Buying and Selling Activity at Voyager Therapeutics

Voyager Therapeutics Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $6.69

$6.65

$7.38

50 Day Range

MA: $6.63

$5.77

$8.07

2 Week Range

Now: $6.69

$5.71

$11.72

Volume

698,244 shs

Average Volume

642,204 shs

Market Capitalization

$364.83 million

P/E Ratio

9.42

Dividend Yield

N/A

Beta

0.89

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.